Published • loading... • Updated
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
Enliven will present ENABLE Phase 1 findings on safety, tolerability and dose selection for ELVN-001, a study in previously treated chronic myeloid leukemia patients.
- On Monday, August 31, 2026, Enliven Therapeutics announced it will present ENABLE Phase 1 data for ELVN-001 at the Society of Hematologic Oncology Annual Meeting in Houston, Texas, September 9-12, 2026.
- The ENABLE study evaluates safety and tolerability of ELVN-001, a selective kinase inhibitor designed to target the ABL1 gene fusion that drives Chronic Myeloid Leukemia in previously treated patients.
- Presenter Fadi Haddad will lead oral and poster presentations on September 9 and 10, 2026, sharing data previously presented at the European Hematology Association 2026 Congress.
- ELVN-001 targets the T315I mutation, which resists most approved TKIs, while secondary ENABLE endpoints include measuring major molecular response and BCR::ABL1 transcript levels.
- Enliven aims to address unmet Chronic Myeloid Leukemia needs with a precision medicine approach; data will be available on the "Program Presentations & Publications" section of the company's website following presentation.
Insights by Ground AI
13 Articles
13 Articles
cachevalleydaily.com+10 Reposted by 10 other sources
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
BURLINGAME, Calif., Aug. 31, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that the Company will present data from the…
Coverage Details
Total News Sources13
Leaning Left2Leaning Right0Center11Last UpdatedBias Distribution85% Center
Bias Distribution
- 85% of the sources are Center
85% Center
15%
C 85%
Factuality
To view factuality data please Upgrade to Premium
